- Home
- PAVS vs LCTX Comparison
PAVS vs LCTX Comparison
Compare PAVS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVS
- LCTX
- Stock Information
- Founded
- PAVS 2004
- LCTX 1990
- Country
- PAVS United States
- LCTX United States
- Employees
- PAVS N/A
- LCTX N/A
- Industry
- PAVS Medicinal Chemicals and Botanical Products
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PAVS Health Care
- LCTX Health Care
- Exchange
- PAVS Nasdaq
- LCTX Nasdaq
- Market Cap
- PAVS 89.6M
- LCTX 95.2M
- IPO Year
- PAVS 2019
- LCTX N/A
- Fundamental
- Price
- PAVS $1.03
- LCTX $0.45
- Analyst Decision
- PAVS
- LCTX Strong Buy
- Analyst Count
- PAVS 0
- LCTX 5
- Target Price
- PAVS N/A
- LCTX $4.20
- AVG Volume (30 Days)
- PAVS 26.8K
- LCTX 904.3K
- Earning Date
- PAVS 01-01-0001
- LCTX 05-13-2025
- Dividend Yield
- PAVS N/A
- LCTX N/A
- EPS Growth
- PAVS N/A
- LCTX N/A
- EPS
- PAVS N/A
- LCTX N/A
- Revenue
- PAVS $6,613,273.00
- LCTX $9,499,000.00
- Revenue This Year
- PAVS N/A
- LCTX N/A
- Revenue Next Year
- PAVS N/A
- LCTX $232.66
- P/E Ratio
- PAVS N/A
- LCTX N/A
- Revenue Growth
- PAVS 2.50
- LCTX 6.19
- 52 Week Low
- PAVS $0.32
- LCTX $0.37
- 52 Week High
- PAVS $1.50
- LCTX $1.40
- Technical
- Relative Strength Index (RSI)
- PAVS 17.87
- LCTX 47.88
- Support Level
- PAVS $1.22
- LCTX $0.37
- Resistance Level
- PAVS $1.40
- LCTX $0.48
- Average True Range (ATR)
- PAVS 0.06
- LCTX 0.04
- MACD
- PAVS -0.03
- LCTX 0.00
- Stochastic Oscillator
- PAVS 6.40
- LCTX 49.73
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.